Stockscreener 앱 받기
1.21
6.14%
0.07
시간 외 거래:
1.20
-0.01
-0.83%
전일 마감가:
$1.14
열려 있는:
$1.17
하루 거래량:
1.20M
Relative Volume:
2.66
시가총액:
$87.47M
수익:
$208.60K
순이익/손실:
$-58.59M
주가수익비율:
-1.3204
EPS:
-0.9164
순현금흐름:
$-47.11M
1주 성능:
+27.37%
1개월 성능:
+27.91%
6개월 성능:
-3.20%
1년 성능:
+10.00%
1일 변동 폭
$1.14
$1.25
1주일 범위
$0.9545
$1.25
52주 변동 폭
$0.7113
$1.94
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.21 | 82.41M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | 재개 | H.C. Wainwright | Buy |
| 2025-05-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-02-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-06 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | 개시 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-04-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-06-05 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-01-29 | 개시 | Robert W. Baird | Outperform |
| 2018-12-10 | 개시 | Credit Suisse | Outperform |
| 2018-07-13 | 개시 | BMO Capital Markets | Outperform |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-28 | 개시 | SunTrust | Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Inflarx N V 주식(IFRX)의 최신 뉴스
InflaRx NV stock (NL0012661870): Why does its anti-inflammatory pipeline matter more now for biotech - AD HOC NEWS
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition - TipRanks
InflaRx (Nasdaq: IFRX) reports izicopan data showing no CYP3A4 time‑dependent inhibition - Stock Titan
New lab data point to lower liver toxicity risk for InflaRx pill - Stock Titan
InflaRx NV stock: Why this biotech innovator merits your watchlist now - AD HOC NEWS
InflaRx receives Nasdaq notification - MSN
Investment Review: Is InflaRx NV a top pick in the sector2026 Highlights & AI Forecasted Stock Moves - baoquankhu1.vn
IFRX Technical Analysis & Stock Price Forecast - Intellectia AI
InflaRx NV stock: Biotech innovator or high-risk bet? - AD HOC NEWS
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP - TipRanks
InflaRx (NASDAQ: IFRX) 2026 AGM to expand share pool, renew buyback - Stock Titan
InflaRx N : Dutch Board Report including KPMG Auditor Report 2025 (InflaRx N.V. Dutch Board Report + Auditor Report 2025) - marketscreener.com
InflaRx N : Long-term Incentive Plan “LTIP 2026” (LTIP 2026 FINAL) - marketscreener.com
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - bitget.com
IFRX Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
InflaRx presents phase 3 vilobelimab data at dermatology meeting By Investing.com - Investing.com South Africa
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting - Bitget
InflaRx presents phase 3 vilobelimab data at dermatology meeting - Investing.com
InflaRx Highlights Clinical Activity of Vilobelimab in - GlobeNewswire
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Sell Signal: Can InflaRx NV deliver consistent dividends2026 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Treasury Yields: Can InflaRx NV sustain earnings growth2026 Earnings Surprises & Daily Stock Momentum Reports - baoquankhu1.vn
Can InflaRx's Vilobelimab Stage A Revival In Pyoderma Gangrenosum? - RTTNews
HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
Analyst Upgrade: Is InflaRx NV a top pick in the sector2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
If You Invested $1,000 in Inflarx (IFRX) - Stock Titan
Aug Shorts: Can InflaRx NV sustain earnings growthMarket Movement Recap & Community Trade Idea Sharing - baoquankhu1.vn
Bear Alert: Is InflaRx NV a top pick in the sector2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
InflaRx NV (IFRX) reports Q4 loss, lags revenue estimates - MSN
Raymond James raises Inflarx stock price target on drug trial data - Investing.com India
Raymond James raises Inflarx stock price target on drug trial data By Investing.com - Investing.com South Africa
InflaRx Survival Hopes Rest On Izicopan - Citeline News & Insights
InflaRx (NASDAQ:IFRX) Given New $14.00 Price Target at Guggenheim - MarketBeat
Guggenheim cuts Inflarx stock price target on model update to $14 By Investing.com - Investing.com South Africa
Guggenheim cuts Inflarx stock price target on model update to $14 - Investing.com Canada
Q1 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
InflaRx (IFRX) posts 2025 loss, relies on cash runway and grants - Stock Titan
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
IFRX: Izicopan's promising Phase 2a data drives strategic focus and extends cash runway to mid-2027 - TradingView
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Meets Expectations - MarketBeat
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027 - TipRanks
Inflarx reports full year 2025 results and highlights key achievements and expected milestones - marketscreener.com
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - The Manila Times
InflaRx (IFRX) narrows 2025 loss, shifts focus to izicopan growth - Stock Titan
IFRX: Izicopan advances as the lead asset with strong Phase 2a data, cost cuts, and extended cash runway - TradingView
After focusing on izicopan, InflaRx says cash lasts until mid-2027 - Stock Titan
InflaRx to present Phase 3 pyoderma gangrenosum data at AAD By Investing.com - Investing.com South Africa
Inflarx N V (IFRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):